High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre

Eur J Neurol. 2004 Jul;11(7):475-7. doi: 10.1111/j.1468-1331.2004.00813.x.

Abstract

The aim of this study was to investigate the efficacy of riboflavin for the prevention of migraine. An open label study was performed in a specialized outpatient clinic. Patients received 400 mg riboflavin capsules per day. Headache frequency, duration, intensity and the use of abortive drugs were recorded at baseline and 3 and 6 months after treatment. Headache frequency was significantly reduced from 4 days/month at baseline to 2 days/month after 3 and 6 months (P < 0.05). The use of abortive drugs decreased from 7 units/month to 4.5 units/month after 3 and 6 months of treatment (P < 0.05). In contrast, headache hours and headache intensity did not change significantly. We could demonstrate a significant reduction of headache frequency following riboflavin treatment. In addition, the number of abortive anti-migraine tablets was reduced. In line with previous studies our findings show that riboflavin is a safe and well-tolerated alternative in migraine prophylaxis.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Ambulatory Care Facilities
  • Female
  • Humans
  • Male
  • Middle Aged
  • Migraine Disorders / prevention & control*
  • Photosensitizing Agents / administration & dosage*
  • Riboflavin / administration & dosage*
  • Treatment Outcome

Substances

  • Photosensitizing Agents
  • Riboflavin